Mirtazapine for Sleep: What You Need to Know
How mirtazapine's histamine, alpha-2, and serotonin-receptor actions affect sleep, what newer insomnia trials show, and the trade-offs worth discussing.

In this article
When poor sleep and depression overlap, a medicine that may help with both can be worth discussing. Mirtazapine is one such option. Its sleep-promoting effects have a different explanation from those of many sleeping pills—and understanding that difference can help you weigh potential relief against next-day sleepiness, appetite changes, and other trade-offs.
What is mirtazapine?
Mirtazapine, also known as Remeron, is an antidepressant approved in the United States for major depressive disorder in adults. Using it specifically for insomnia is off-label. That means the sleep indication is not FDA-approved; it does not mean a clinician cannot consider it when its benefits and risks fit the situation.156
How does mirtazapine work? An in-depth look
Mirtazapine acts at several receptor systems rather than one simple ‘sleep switch.’ An antagonist blocks a receptor's activation. Here, blocking different receptors can have different consequences: reducing a wakefulness signal at one site while removing inhibitory feedback at another.34
H1 histamine blockade: turning down a wakefulness signal
Histamine is not only involved in allergies; in the brain, H1 signaling also supports wakefulness. Mirtazapine strongly occupies H1 receptors, helping explain its sedating effects. In a small PET imaging study of healthy men, a single 15 mg dose produced about 80–90% H1 receptor occupancy in the cerebral neocortex. Occupancy was associated with subjective sleepiness.2
That is a useful human finding linking receptor engagement to how someone feels. It also explains why the same action can be helpful at bedtime yet unwelcome the next morning. Receptor occupancy is not the same outcome as sustained improvement in insomnia, which needs clinical sleep studies.256
Alpha-2 blockade: releasing the brakes on neurotransmission
Presynaptic alpha-2 receptors help regulate transmitter release. Autoreceptors provide feedback on a neuron's own transmitter system; heteroreceptors can regulate a different transmitter system. Mirtazapine blocks inhibitory alpha-2 receptors, a mechanism associated with enhanced noradrenergic and serotonergic transmission.34
Preclinical research describes two routes to increased serotonin output: indirect stimulation of serotonin neurons through noradrenergic pathways, and blockade of alpha-2 heteroreceptors on serotonin terminals. Think of this as easing a feedback brake, not simply pouring more serotonin into the brain. These circuit findings come from animal experiments and help explain the proposed antidepressant mechanism.3
Serotonin receptors: why this is not an SSRI
Mirtazapine also blocks 5-HT2 and 5-HT3 serotonin receptors. Unlike an SSRI, its defining action is not serotonin-reuptake inhibition. Its combination of enhanced transmitter signaling and selective receptor blockade is often described as a noradrenergic and specific serotonergic profile.34
A common explanation is that blocking 5-HT2 and 5-HT3 leaves other serotonin pathways, including 5-HT1-mediated signaling, relatively available. This does not mean mirtazapine directly activates 5-HT1A receptors: its affinity there is low. The receptor pattern helps distinguish it from other antidepressants, while H1 blockade is particularly relevant to sleepiness.14
Why sleepiness and antidepressant benefit follow different timelines
Sleepiness can occur early, whereas the full antidepressant benefit may take several weeks. Feeling sedated is therefore not a test of whether depression has responded. Mirtazapine's half-life is approximately 20–40 hours, so a bedtime dose can still affect alertness the next day.128
What does the evidence show for sleep?
The 2025 DREAMING trial enrolled 80 adults across three groups: low-dose mirtazapine, amitriptyline, or placebo. Participants had insomnia with sleep-maintenance problems despite insufficient benefit from non-drug treatment. At six weeks, mirtazapine 7.5–15 mg/day improved insomnia severity more than placebo, with a six-point between-group difference on the Insomnia Severity Index.5
The encouraging part is a clinically meaningful short-term improvement. The important follow-up finding is that the difference from placebo was no longer statistically significant from 12 weeks onward. That supports a planned review of benefit, rather than assuming a helpful early response will necessarily persist for months.5
The MIRAGE trial studied 60 adults aged 65 or older for 28 days. Mirtazapine 7.5 mg improved insomnia severity and several self-reported sleep measures compared with placebo. However, six people taking mirtazapine stopped because of adverse effects, compared with one taking placebo. These results offer a reason for hope alongside a practical reminder to monitor tolerability.6
What dose is used—and are lower doses always more sedating?
The insomnia trials above used 7.5–15 mg, while the approved starting dose for depression is 15 mg nightly, with a maximum of 45 mg daily. Study doses are context, not instructions to start or adjust treatment yourself.156
You may hear that low doses are sedating and higher doses become activating. That is a proposed explanation based on competing receptor effects, not a dependable rule for an individual. An exploratory adverse-event analysis did not support a simple increase in activating effects with higher doses; it was not a controlled test establishing the ideal sleep dose. Do not increase the dose to try to ‘cancel out’ grogginess.7
Side effects: what matters in everyday life
Common issues include drowsiness, dizziness, dry mouth, constipation, increased appetite, and weight gain. A medicine that helps sleep can still be a poor fit if mornings become unsafe or appetite changes are difficult. Bring those concerns into the decision from the start.8
Avoid alcohol, and do not drive until you know its effects. Review other sedatives, opioids, sleep aids, antidepressants, and supplements with a pharmacist. MAOI combinations are contraindicated, and other serotonergic medicines can increase serotonin-syndrome risk.18
Precautions and symptoms that need attention
Discuss bipolar disorder, kidney or liver disease, seizures, glaucoma, heart-rhythm risks, pregnancy, and breastfeeding before treatment. Contact your clinician promptly for new agitation, unusually elevated mood, worsening depression, suicidal thoughts, or fever with sore throat. Seek urgent care for severe allergic symptoms, seizures, or fever with confusion and muscle rigidity. If safety is at immediate risk, seek emergency help.8
Do not stop suddenly. Withdrawal symptoms can occur, and a prescriber-guided gradual reduction is generally recommended.8
Where it fits in a longer-term sleep plan
Mirtazapine may be particularly worth discussing when depression, poor sleep, and reduced appetite occur together. If insomnia is the main problem, ask why this option fits better than alternatives and agree on when to review sleep quality, daytime functioning, and side effects.568
Cognitive behavioral therapy for insomnia (CBT-I) has a strong guideline recommendation for chronic insomnia. It includes structured work on sleep-related thoughts and behaviors—not just advice to put away your phone. Medication can be part of a broader plan while persistent sleep problems receive proper assessment.9
The takeaway
Mirtazapine offers a genuinely different medication profile, with H1 blockade closely linked to sleepiness and other receptor actions relevant to depression treatment. Short-term insomnia findings are encouraging. The goal is not simply feeling sedated—it is better nights and more manageable days, with benefits that remain worth the trade-offs.
By Birk Gundersen RN, BSN.
Words worth knowing
Cognitive behavioral therapy (CBT)
A structured therapy that helps people notice patterns between thoughts, feelings, and actions, then practice more helpful responses.
Insomnia
A sleep disorder involving persistent difficulty falling asleep, staying asleep, or getting restorative sleep.
References
- DailyMed. Remeron/RemeronSolTab prescribing information: indication, dosing, pharmacology, pharmacokinetics, and interactions.
- Sato H, et al. Histamine H1 receptor occupancy by fluvoxamine and mirtazapine: a PET study in healthy volunteers. Psychopharmacology. 2013;230:227–234.
- De Boer T, et al. The alpha2-selective adrenoceptor antagonist Org 3770 (mirtazapine) enhances noradrenergic and serotonergic transmission. Human Psychopharmacology. 1995. Preclinical research.
- National Cancer Institute. Mirtazapine: pharmacological definition and receptor actions.
- Bakker MH, et al. Effectiveness of low-dose amitriptyline and mirtazapine for insomnia in general practice: the randomized DREAMING trial. British Journal of General Practice. 2025.
- Nguyen PVQ, et al. Mirtazapine for chronic insomnia in older adults: the randomized MIRAGE study. Age and Ageing. 2025;54:afaf050.
- Shuman M, et al. Relationship between mirtazapine dose and incidence of adrenergic side effects: an exploratory analysis. Mental Health Clinician. 2019;9:41–47.
- MedlinePlus. Mirtazapine: patient instructions, precautions, side effects, and discontinuation.
- Edinger JD, et al. Behavioral and psychological treatments for chronic insomnia disorder in adults: an AASM clinical practice guideline. 2021.
